Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [5] - The company's lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator [5] - Nektar's pipeline includes additional candidates such as a preclinical bivalent TNFR2 antibody and bispecific programs, NKTR-0165 and NKTR-0166, as well as NKTR-422, a modified hematopoietic colony stimulating factor [5] Product Development - Rezpegaldesleukin is being developed as a self-administered injection for various autoimmune and inflammatory diseases [3] - It is currently evaluated in two Phase 2b clinical trials: the REZOLVE-AD study for moderate-to-severe atopic dermatitis and the REZOLVE-AA study for severe-to-very-severe alopecia areata [3] - The FDA has granted Fast Track designation for rezpegaldesleukin for treating patients aged 12 and older with moderate-to-severe atopic dermatitis [4] Upcoming Events - Nektar Therapeutics will host a virtual investor and analyst event with Type 1 Diabetes experts on February 24, 2025 [1] - The event will be led by Nektar's Chief Research & Development Officer, Jonathan Zalevsky, and will feature leading diabetes experts [1][7]